1. The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement.
- Author
-
Klontz KC, DeBeck HJ, LeBlanc P, Mogen KM, Wolpert BJ, Sabo JL, Salter M, Seelman SL, Lance SE, Monahan C, Steigman DS, and Gensheimer K
- Subjects
- Adult, Anti-Obesity Agents poisoning, Chemical and Drug Induced Liver Injury etiology, Chemical and Drug Induced Liver Injury surgery, Chemistry, Pharmaceutical legislation & jurisprudence, Disease Outbreaks statistics & numerical data, Female, Hawaii epidemiology, Humans, Liver Failure, Acute mortality, Liver Transplantation statistics & numerical data, Male, Middle Aged, Population Surveillance methods, United States epidemiology, Young Adult, Adverse Drug Reaction Reporting Systems legislation & jurisprudence, Amides poisoning, Amines poisoning, Chemical and Drug Induced Liver Injury epidemiology, Dietary Supplements poisoning, Drug Approval legislation & jurisprudence, Liver Failure, Acute chemically induced, United States Food and Drug Administration legislation & jurisprudence
- Abstract
Objective: Liver disease is a potential complication from using dietary supplements. This study investigated an outbreak of non-viral liver disease associated with the use of OxyELITE Pro(TM), a dietary supplement used for weight loss and/or muscle building., Methods: Illness details were ascertained from MedWatch reports submitted to the U.S. Food and Drug Administration (FDA) describing consumers who ingested OxyELITE Pro alone or in combination with other dietary supplements. FDA's Forensic Chemistry Center analyzed samples of OxyELITE Pro., Results: From February 2012 to February 2014, FDA received 114 reports of adverse events of all kinds involving consumers who ingested OxyELITE Pro. The onset of illness for the first report was December 2010 and for the last report was January 2014. Thirty-three states, two foreign nations, and Puerto Rico submitted reports. Fifty-five of the reports (48%) described liver disease in the absence of viral infection, gallbladder disease, autoimmune disease, or other known causes of liver damage. A total of 33 (60%) of these patients were hospitalized, and three underwent liver transplantation. In early 2013, OxyELITE Pro products entered the market with a formulation distinct from products sold previously. The new formulation replaced 1,3-dimethylamylamine with aegeline. However, the manufacturer failed to submit to FDA a required "new dietary ingredient" notice for the use of aegeline in OxyELITE Pro products. Laboratory analysis identified no drugs, poisons, pharmaceuticals, toxic metals, usnic acid, N-Nitroso-fenfluramine, pyrrolizidine alkaloids, aristocholic acid, or phenethylamines in the products., Conclusions: Vigilant surveillance is required for adverse events linked to the use of dietary supplements.
- Published
- 2015
- Full Text
- View/download PDF